C:\Users\Utente\Desktop\Meta-analisi\Tab e fig riviste e finite\S1\Figura_S1.TIF

**Figure S1.** Flow-chart of study selection.

C:\Users\Utente\Desktop\Meta-analisi\Tab e fig riviste e finite\Figura_S2.tif

**Figure S2.** Meta-analysis of SGLT2i trials on CV secondary outcomes stratified by the presence of established ASCVD or multiple CV risk factors. (A) Non-fatal MI; (B) Non-fatal stroke; (C) CV death; D) All cause death.

CV: cardiovascular; MI: myocardial infarction; ASCVD: atherosclerotic CV disease; MRF: multiple risk factors.

C:\Users\Utente\Desktop\Meta-analisi\Tab e fig riviste e finite\Figura_S3.tif

**Figure S3.** Meta-analysis of SGLT2i trials on CV secondary outcomes stratified by the presence (HF+) or not (HF-) of HF at baseline. (A) CV death; (B) All-cause death.

CV: cardiovascular; HF: heart failure.

C:\Users\Utente\Desktop\Meta-analisi\Tab e fig riviste e finite\Figure_S5 (1).TIF

C:\Users\Utente\Desktop\Meta-analisi\Tab e fig riviste e finite\Figure_S5(2).TIF

**Figure S4.** Safety analysis. Effects of SGLT2i on (A) amputation, (B) bone fractures, (C) pancreatitis, (D) severe hypoglycemia, (E) urinary tract infections, (F) volume depletion, (G) diabetic ketoacidosis, (H) genital tract infections.